Diltiazem Hydrochloride Capsule, Extended Release
NDC Package 48433-032-20

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Diltiazem Hydrochloride capsules is diltiazem hydrochloride extended-release capsules (Twice-a-Day Dosage) are indicated for the treatment of hypertension. This formulation utilizes a capsule, extended release delivery system. Marketed by Safecor Health Llc, this product is identified by NDC 48433-032 and is authorized under FDA application ANDA074910.

Identification & Billing

NDC Package Code
48433-032-20
Package Description
100 BLISTER PACK in 1 CARTON / 1 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK (48433-032-01)
Product Code
11-Digit Billing Format
48433003220
RxNorm Crosswalk
  • RxCUI: 830865 - dilTIAZem hydrochloride 60 MG 12HR Extended Release Oral Capsule
  • RxCUI: 830865 - 12 HR diltiazem hydrochloride 60 MG Extended Release Oral Capsule
  • RxCUI: 830865 - diltiazem hydrochloride 60 MG 12 HR Extended Release Oral Capsule
  • RxCUI: 830869 - dilTIAZem hydrochloride 90 MG 12HR Extended Release Oral Capsule
  • RxCUI: 830869 - 12 HR diltiazem hydrochloride 90 MG Extended Release Oral Capsule

Clinical Specifications

Proprietary Name
Diltiazem Hydrochloride
Non-Proprietary Name
Diltiazem Hydrochloride
Substance Name
Diltiazem Hydrochloride
Dosage Form
Capsule, Extended Release - A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug (or drugs) in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Diltiazem hydrochloride extended-release capsules (Twice-a-Day Dosage) are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medications, such as diuretics.

Regulatory & Marketing

Labeler Name
Safecor Health Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA074910
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
02-02-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 48433-032-20 identifies a specific commercial package of 100 blister pack in 1 carton / 1 capsule, extended release in 1 blister pack (48433-032-01) of Diltiazem Hydrochloride, a human prescription drug labeled by Safecor Health Llc. This capsule, extended release is formulated for oral use and contains diltiazem hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Safecor Health Llc on February 02, 2026. The current certification is valid through December 31, 2027.

How is this Safecor Health Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 48433003220. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
48433-032-20
11-Digit CMS (5-4-2)
48433-0032-20

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.